Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 10/20 | 0.45 |
| ▸ | ACLY | P53396 | 2/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1466360 | 0.93 | AKR1C3 (0.60) | AKR1C3AKR1C1LMNASMN1; SMN2HTR6 | |
| SCHEMBL3146040 | 0.90 | AKR1C3 (0.51) | AKR1C3AKR1C1LMNASMN1; SMN2HTR6 | |
| SCHEMBL12748713 | 0.90 | HTR6 (0.54) | AKR1C3AKR1C1LMNASMN1; SMN2HTR6 | |
| SCHEMBL3132165 | 0.89 | AKR1C3 (0.50) | AKR1C3AKR1C1LMNASMN1; SMN2HTR6 | |
| SCHEMBL12748623 | 0.86 | AKR1C3 (0.78) | AKR1C3AKR1C1LMNASMN1; SMN2HTR6 | |
| SCHEMBL6769055 | 0.83 | LMNA (0.71) | AKR1C3AKR1C1LMNASMN1; SMN2HTR6 | |
| SCHEMBL3362896 | 0.80 | HTR6 (0.44) | HTR6KLK7CA2CA9 | |
| SCHEMBL1041051 | 0.80 | LMNA (0.53) | AKR1C3AKR1C1LMNASMN1; SMN2HTR6 | |
| SCHEMBL3137579 | 0.78 | FLT1 (0.46) | LMNASMN1; SMN2HTR6ACLYMEN1 | |
| SCHEMBL7135129 | 0.78 | LMNA (0.48) | AKR1C3AKR1C1LMNASMN1; SMN2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118060-B1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2010-10-06 | — | — | EP | claimed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | claimed |
| CN-101605759-A | 1-benzenesulfonyl-1H-indole derivatives as inhibitors of CCR9 activity | NOVARTIS AG (CH) | 2009-12-16 | — | — | CN | claimed |
| EP-2118060-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2009-11-18 | — | — | EP | claimed |
| WO-2008095908-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | claimed |
| EP-2118060-B1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| EP-2118060-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008095908-A1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | CCR9, IDO1, CCR10 | AKR1C3 1773/4885AKR1C1 2251/4885LMNA 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.